Shilpa Gupta MDDirector, Genitourinary Medical Oncology, Taussig Cancer Institute; Co-Leader, Genitourinary Oncology Program, Cleveland Clinic, Cleveland, Ohio
Dr. Shilpa Gupta is the Director of the Genitourinary Medical Oncology at the Taussig Cancer Institute (TCI) in Cleveland, Ohio, and Co-Leader of the Genitourinary Oncology Program at the Cleveland Clinic.
Dr. Gupta obtained her medical degree at the Lady Hardinge Medical College in New Delhi, India, and completed a residency in internal medicine at the University of Connecticut Health Center. She completed her hematology–oncology fellowship at Georgetown University and Thomas Jefferson University, followed by a genitourinary oncology translational research fellowship at Thomas Jefferson University. Prior to joining TCI, she was Associate Professor and Lead for the Solid Tumor Phase 1 Program at the Masonic Cancer Center at the University of Minnesota.
Dr. Gupta is actively involved in research, where her interests focus on novel drug development and understanding biomarkers of response and resistance to therapies in bladder cancer. She has led several investigator-initiated trials in genitourinary cancers and has leadership roles in NCI trials, among others conducted by various clinical trial cooperative groups.
Her research work has been published in peer-reviewed journals, including the Journal of Clinical Oncology, Lancet Oncology, and Clinical Cancer Research. Dr. Gupta is active in several professional organizations, which include the American Society of Clinical Oncology (ASCO), American Urologic Association (AUA), American Association of Cancer Research (AACR), Society of Urologic Oncology (SUO), Society of Immunotherapy for Cancer (SITC), Prostate Cancer Foundation (PCF), and the European society of Medical Oncology (ESMO).
Recent Contributions to PracticeUpdate:
- 2022 Top Story in Bladder Cancer: Revisiting PARP Inhibitors in Bladder Cancer
- ESMO 2022: Recommendations From Dr. Shilpa Gupta for Genitourinary Cancer
- Cabozantinib Plus Nivolumab After Prior Checkpoint Inhibition
- Tumor Mutational Burden as a Predictive Biomarker in First-Line Metastatic Urothelial Carcinoma
- Neoadjuvant Enfortumab Vedotin for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer
- Nivolumab, Gemcitabine, and Cisplatin for Muscle-Invasive Bladder Cancer Undergoing Cystectomy
- Adjuvant Nivolumab After Chemo-Radiation for Localized Muscle-Invasive Bladder Cancer
- 2021 Top Story in Bladder Cancer: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
- Immunotherapy and Modern Imaging in Non-Muscle-Invasive Bladder Cancer Management
- Preoperative Dose High and Low Comparisons for Ipilimumab and Nivolumab for Urothelial Carcinoma